IDEAS home Printed from https://ideas.repec.org/p/hal/wpaper/halshs-01878942.html
   My bibliography  Save this paper

Impact of type of 2 diabetes on health expenditure : an estimation based on individual administrative data

Author

Listed:
  • François-Olivier Baudot

    (ERUDITE - Equipe de Recherche sur l’Utilisation des Données Individuelles en lien avec la Théorie Economique - UPEM - Université Paris-Est Marne-la-Vallée - UPEC UP12 - Université Paris-Est Créteil Val-de-Marne - Paris 12, Caisse Nationale d'Assurance Maladie - Caisse Nationale d'Assurance Maladie)

  • Anne-Sophie Aguade

    (Caisse Nationale d'Assurance Maladie - Caisse Nationale d'Assurance Maladie)

  • Thomas Barnay

    (ERUDITE - Equipe de Recherche sur l’Utilisation des Données Individuelles en lien avec la Théorie Economique - UPEM - Université Paris-Est Marne-la-Vallée - UPEC UP12 - Université Paris-Est Créteil Val-de-Marne - Paris 12, TEPP - Travail, Emploi et Politiques Publiques - UPEM - Université Paris-Est Marne-la-Vallée - CNRS - Centre National de la Recherche Scientifique)

  • Christelle Gastaldi-Menager

    (Caisse Nationale d'Assurance Maladie - Caisse Nationale d'Assurance Maladie)

  • Anne Fagot-Campagna

    (Caisse Nationale d'Assurance Maladie - Caisse Nationale d'Assurance Maladie)

Abstract

Only limited data are available in France on the incidence and health expenditure of type 2 diabetes. The objective of this study, based on national health insurance administrative database, is to describe the expenditure reimbursed to patients newly treated for type 2 diabetes and the proportion of expenditure attributable to diabetes. The study is conducted over a 6-year period from 2008, the year of incidence of treated diabetes, to 2014. Type 2 diabetic patients aged 45 years and older are identified on the basis of their drug consumption. To estimate expenditure attributable to diabetes, a matched control group is selected among more than 13 million beneficiaries over 44 years old not taking antidiabetic treatment. The expenditure attributable to diabetes is estimated by two methods: simple comparison of reimbursed health expenditure between both groups, and a difference-in-differences method including control variables. The cohort of incident type 2 diabetic patients comprises 170,013 patients in 2008. Mean global reimbursed expenditure is €4700 per patient in 2008 and €5500 in 2015. Expenditure attributable to diabetes, estimated by direct comparison with controls, is €1500 in the first year. We, thus, observe a decrease in the following year due to decreased hospitalisations, and then expenditure increase by an average of 7% per year to reach €1900 in the eighth year after the initiation of treatment.
(This abstract was borrowed from another version of this item.)

Suggested Citation

  • François-Olivier Baudot & Anne-Sophie Aguade & Thomas Barnay & Christelle Gastaldi-Menager & Anne Fagot-Campagna, 2018. "Impact of type of 2 diabetes on health expenditure : an estimation based on individual administrative data," Working Papers halshs-01878942, HAL.
    • Handle: RePEc:hal:wpaper:halshs-01878942
    Note: View the original document on HAL open archive server: https://shs.hal.science/halshs-01878942
    as

    Download full text from publisher

    File URL: https://shs.hal.science/halshs-01878942/document
    Download Restriction: no
    ---><---

    Other versions of this item:

    References listed on IDEAS

    as
    1. Betty Tao & Massimo Pietropaolo & Mark Atkinson & Desmond Schatz & David Taylor, 2010. "Estimating the Cost of Type 1 Diabetes in the U.S.: A Propensity Score Matching Method," PLOS ONE, Public Library of Science, vol. 5(7), pages 1-11, July.
    2. D. Sittig & H. Friedel & J. Wasem, 2015. "Prevalence and treatment costs of type 2 diabetes in Germany and the effects of social and demographical differences," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(3), pages 305-311, April.
    3. Ebere Akobundu & Jing Ju & Lisa Blatt & C. Mullins, 2006. "Cost-of-Illness Studies," PharmacoEconomics, Springer, vol. 24(9), pages 869-890, September.
    4. A. Marcellusi & R. Viti & A. Mecozzi & F. Mennini, 2016. "The direct and indirect cost of diabetes in Italy: a prevalence probabilistic approach," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(2), pages 139-147, March.
    5. repec:cup:judgdm:v:4:y:2009:i:1:p:1-19 is not listed on IDEAS
    6. Manel Mata-Cases & Marc Casajuana & Josep Franch-Nadal & Aina Casellas & Conxa Castell & Irene Vinagre & Dídac Mauricio & Bonaventura Bolíbar, 2016. "Direct medical costs attributable to type 2 diabetes mellitus: a population-based study in Catalonia, Spain," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(8), pages 1001-1010, November.
    7. Till Seuring & Olga Archangelidi & Marc Suhrcke, 2015. "The Economic Costs of Type 2 Diabetes: A Global Systematic Review," PharmacoEconomics, Springer, vol. 33(8), pages 811-831, August.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Ugolini, Cristina & Lippi Bruni, Matteo & Leucci, Anna Caterina & Fiorentini, Gianluca & Berti, Elena & Nobilio, Lucia & Moro, Maria Luisa, 2019. "Disease management in diabetes care: When involving GPs improves patient compliance and health outcomes," Health Policy, Elsevier, vol. 123(10), pages 955-962.
    2. Viera Ivanková & Rastislav Kotulič & Jaroslav Gonos & Martin Rigelský, 2019. "Health Care Financing Systems and Their Effectiveness: An Empirical Study of OECD Countries," IJERPH, MDPI, vol. 16(20), pages 1-22, October.
    3. Elsa Bouée-Benhamiche & Philippe Jean Bousquet & Salah Ghabri, 2020. "Economic Evaluations of Anticancer Drugs Based on Medico-Administrative Databases: A Systematic Literature Review," Applied Health Economics and Health Policy, Springer, vol. 18(4), pages 491-508, August.
    4. Karen Eggleston & Brian K. Chen & Chih-Hung Chen & Ying Isabel Chen & Talitha Feenstra & Toshiaki Iizuka & Janet Tin Kei Lam & Gabriel M. Leung & Jui-fen Rachel Lu & Beatriz Rodriguez-Sanchez & Jeroen, 2020. "Are quality-adjusted medical prices declining for chronic disease? Evidence from diabetes care in four health systems," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(5), pages 689-702, July.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Gourzoulidis, George & Kourlaba, Georgia & Stafylas, Panagiotis & Giamouzis, Gregory & Parissis, John & Maniadakis, Nikolaos, 2017. "Association between copayment, medication adherence and outcomes in the management of patients with diabetes and heart failure," Health Policy, Elsevier, vol. 121(4), pages 363-377.
    2. Seuring, Till & Serneels, Pieter & Suhrcke, Marc, 2019. "The impact of diabetes on labour market outcomes in Mexico: A panel data and biomarker analysis," Social Science & Medicine, Elsevier, vol. 233(C), pages 252-261.
    3. Charmaine Shuyu Ng & Matthias Paul Han Sim Toh & Yu Ko & Joyce Yu-Chia Lee, 2015. "Direct Medical Cost of Type 2 Diabetes in Singapore," PLOS ONE, Public Library of Science, vol. 10(3), pages 1-11, March.
    4. Mennini, Francesco Saverio & Gitto, Lara, 2022. "Approaches to Estimating Indirect Costs in Healthcare: Motivations for Choice," MPRA Paper 112129, University Library of Munich, Germany.
    5. Margherita d’Errico & Milena Pavlova & Federico Spandonaro, 2022. "The economic burden of obesity in Italy: a cost-of-illness study," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 23(2), pages 177-192, March.
    6. Joan Gil & Paolo Li Donni & Eugenio Zucchelli, 2019. "Uncontrolled diabetes and health care utilisation: A bivariate latent Markov model approach," Health Economics, John Wiley & Sons, Ltd., vol. 28(11), pages 1262-1276, November.
    7. Ling Jie Cheng & Wenru Wang & Suan Tee Lim & Vivien Xi Wu, 2019. "Factors associated with glycaemic control in patients with diabetes mellitus: A systematic literature review," Journal of Clinical Nursing, John Wiley & Sons, vol. 28(9-10), pages 1433-1450, May.
    8. Gabriela Maria Reis Goncalves & Everton Nunes da Silva, 2018. "Cost of chronic kidney disease attributable to diabetes from the perspective of the Brazilian Unified Health System," PLOS ONE, Public Library of Science, vol. 13(10), pages 1-15, October.
    9. Sanjib Saha & Ulf Gerdtham, 2013. "Cost of illness studies on reproductive, maternal, newborn, and child health: a systematic literature review," Health Economics Review, Springer, vol. 3(1), pages 1-12, December.
    10. A. Marcellusi & F. S. Mennini & P. Sciattella & G. Favato, 2021. "Human papillomavirus in Italy: retrospective cohort analysis and preliminary vaccination effect from real-world data," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(9), pages 1371-1379, December.
    11. Eriksen, Tine Louise Mundbjerg & Gaulke, Amanda & Svensson, Jannet & Skipper, Niels & Thingholm, Peter Rønø, 2023. "Childhood Health Shocks and the Intergenerational Transmission of Inequality," IZA Discussion Papers 16447, Institute of Labor Economics (IZA).
    12. Dixon, Padraig & Harrison, Sean & Hollingworth, William & Davies, Neil M. & Davey Smith, George, 2022. "Estimating the causal effect of liability to disease on healthcare costs using Mendelian Randomization," Economics & Human Biology, Elsevier, vol. 46(C).
    13. Claudiu Morgovan & Smaranda Adina Cosma & Madalina Valeanu & Anca Maria Juncan & Luca Liviu Rus & Felicia Gabriela Gligor & Anca Butuca & Delia Mirela Tit & Simona Bungau & Steliana Ghibu, 2020. "An Exploratory Research of 18 Years on the Economic Burden of Diabetes for the Romanian National Health Insurance System," IJERPH, MDPI, vol. 17(12), pages 1-16, June.
    14. Grégoire Lagasnerie & Anne-Sophie Aguadé & Pierre Denis & Anne Fagot-Campagna & Christelle Gastaldi-Menager, 2018. "The economic burden of diabetes to French national health insurance: a new cost-of-illness method based on a combined medicalized and incremental approach," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(2), pages 189-201, March.
    15. Stuart Keel & Joshua Foreman & Jing Xie & Peter van Wijngaarden & Hugh R Taylor & Mohamed Dirani, 2017. "The Prevalence of Self-Reported Diabetes in the Australian National Eye Health Survey," PLOS ONE, Public Library of Science, vol. 12(1), pages 1-10, January.
    16. Karen Jordan & Christopher G. Fawsitt & Paul G. Carty & Barbara Clyne & Conor Teljeur & Patricia Harrington & Mairin Ryan, 2023. "Cost-effectiveness of metabolic surgery for the treatment of type 2 diabetes and obesity: a systematic review of economic evaluations," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(4), pages 575-590, June.
    17. Sun, Fei & Zhang, Qi, 2023. "Robust transfer learning of high-dimensional generalized linear model," Physica A: Statistical Mechanics and its Applications, Elsevier, vol. 618(C).
    18. Isabelle Chort & Olivier Dagnelie, 2022. "Worms or sugar? Mass deworming treatment doubles the probability to suffer from diabetes ten to fifteen years later," Working Papers hal-03887621, HAL.
    19. Seuring, Till & Serneels, Pieter & Suhrcke, Marc & Bachmann, Max, 2020. "Diabetes, employment and behavioural risk factors in China: Marginal structural models versus fixed effects models," Economics & Human Biology, Elsevier, vol. 39(C).
    20. Désirée Vandenberghe, 2022. "Simulating lifestyle and medical interventions to prevent type-2 diabetes: an economic evaluation for Belgium," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 23(2), pages 237-248, March.

    More about this item

    JEL classification:

    • C23 - Mathematical and Quantitative Methods - - Single Equation Models; Single Variables - - - Models with Panel Data; Spatio-temporal Models
    • H51 - Public Economics - - National Government Expenditures and Related Policies - - - Government Expenditures and Health
    • I18 - Health, Education, and Welfare - - Health - - - Government Policy; Regulation; Public Health

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:hal:wpaper:halshs-01878942. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: CCSD (email available below). General contact details of provider: https://hal.archives-ouvertes.fr/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.